Altshuler Shaham Ltd bought a new position in Biogen during the fourth quarter valued at $25,000.

Source: https://www.americanbankingnews.com/2023/07/28/analysts-set-biogen-inc-nasdaqbiib-pt-at-330-19.html

Altshuler Shaham Ltd purchased a new position in Biogen during the 4th quarter valued at about $25,000.

Source: https://www.americanbankingnews.com/2023/05/12/biogen-nasdaqbiib-price-target-increased-to-350-00-by-analysts-at-argus.html

American International Group Inc. reduced its stake in shares of Biogen Inc. () by 2.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).

Source: https://www.etfdailynews.com/2023/11/03/american-international-group-inc-lowers-holdings-in-biogen-inc-nasdaqbiib/

Arizona State Retirement System’s holdings in Biogen were worth $11,765,000 at the end of the most recent reporting period.

Source: https://www.etfdailynews.com/2023/10/21/arizona-state-retirement-system-purchases-1982-shares-of-biogen-inc-nasdaqbiib/

“Bentonville in Bloom,” is an official event of the 2023 North Carolina Science Festival (NCSciFest), presented by the Biogen Foundation.

Source: https://jocoreport.com/bentonville-to-showcase-the-battlefields-natural-resources/

Biogen Inc. (NASDAQ:BIIB) Shares Bought by Macquarie Group Ltd.

Source: https://www.americanbankingnews.com/2023/03/06/alphacrest-capital-management-llc-boosts-position-in-amn-healthcare-services-inc-nyseamn.html

Biogen is developing lecanemab in partnership with Eisai, with all research, sales, and marketing costs to be shared equally between the two companies.

Source: https://seekingalpha.com/article/4575506-biogen-stock-what-to-do-ahead-of-q4-earnings?source=feed_all_articles

Biogen is one of the key biopharmaceutical companies in developing and commercializing innovative treatments for people living with neurological and neurodegenerative diseases such as spinal muscular atrophy, multiple sclerosis, and Alzheimer's disease.

Source: https://seekingalpha.com/article/4575506-biogen-stock-what-to-do-ahead-of-q4-earnings?source=feed_all_articles

Biogen will find out in July if the FDA has granted its Alzheimer's drug Leqembi full approval.

Source: https://seekingalpha.com/article/4613818-biogen-highs-lows-mounting-expectations-ahead-of-leqembi-decision?source=feed_all_articles

CVA Family Office LLC increased its position in Biogen by 50.0% during the third quarter.

Source: https://www.etfdailynews.com/2023/04/05/allspring-global-investments-holdings-llc-boosts-stake-in-biogen-inc-nasdaqbiib/

Global Expansion Potential: With its international presence, Biogen can introduce Skyclarys across continents, thereby escalating its revenue channels multifold.

Source: https://seekingalpha.com/article/4627497-biogen-q2-2023-analysis-reata-acquisition-financials-and-alzheimers-prospects?source=feed_all_articles

Guggenheim upgraded shares of Biogen from a neutral rating to a buy rating and lifted their price target for the stock from $270.00 to $350.00 in a research note on Monday, May 1st.

Source: https://www.etfdailynews.com/2023/07/28/biogens-biib-buy-rating-reiterated-at-needham-company-llc/

In other Biogen news, EVP Ginger Gregory sold 2,681 shares of the stock in a transaction dated Friday, April 28th.

Source: https://www.etfdailynews.com/2023/06/29/biogen-inc-nasdaqbiib-stock-holdings-lessened-by-national-bank-of-canada-fi/

In other Biogen news, EVP Ginger Gregory sold 5,610 shares of the firm’s stock in a transaction on Monday, November 14th.

Source: https://www.americanbankingnews.com/2023/01/30/caprock-group-inc-cuts-holdings-in-biogen-inc-nasdaqbiib.html

James Investment Research Inc. purchased a new stake in Biogen during the 4th quarter valued at $28,000.

Source: https://www.americanbankingnews.com/2023/06/06/cibc-private-wealth-group-llc-takes-984000-position-in-biogen-inc-nasdaqbiib.html

Massachusetts-based Biogen has gotten the green light for a breakthrough ALS treatment that targets a devastating, ultra-rare genetic form of the progressive neurodegenerative disease.

Source: https://www.coloradohometownweekly.com/2023/04/27/biogen-receives-fda-approval-for-breakthrough-als-treatment-pivotal-moment-in-als-research/

Raymond James Trust N.A. boosted its position in shares of Biogen by 16.4% during the 1st quarter.

Source: https://www.americanbankingnews.com/2023/08/29/biogen-inc-nasdaqbiib-shares-acquired-by-shelton-capital-management.html

Royal Bank of Canada upped their price objective on Biogen from $351.00 to $363.00 and gave the stock an “outperform” rating in a research note on Thursday.

Source: https://www.etfdailynews.com/2023/11/12/biogen-inc-nasdaqbiib-holdings-decreased-by-andra-ap-fonden/

State Street Corp raised its stake in shares of Biogen by 2.8% in the 1st quarter.

Source: https://www.americanbankingnews.com/2023/01/31/d-a-davidson-co-sells-4375-shares-of-biogen-inc-nasdaqbiib.html

Viehbacher, a former Sanofi and GSK executive, was brought on to put Biogen back on track.

Source: https://medcitynews.com/2023/07/biogen-acquisition-rare-disease-neuromuscular-reata/